Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

191 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. Among authors: woerle hj. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T, Sesoko S, Woerle HJ, Dugi KA. Sarashina A, et al. Among authors: woerle hj. Drug Metab Pharmacokinet. 2013;28(3):213-9. doi: 10.2133/dmpk.dmpk-12-rg-082. Epub 2012 Nov 13. Drug Metab Pharmacokinet. 2013. PMID: 23149871 Free article. Clinical Trial.
191 results